KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Consensus Rating of “Hold” from Brokerages

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) have been assigned a consensus rating of “Hold” from the nine ratings firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and three have given a buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $30.60.

Several research firms have weighed in on KALV. JonesTrading lowered KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 30th. HC Wainwright lowered KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the company from $37.00 to $27.00 in a report on Friday, May 1st. Wall Street Zen raised KalVista Pharmaceuticals to a “hold” rating in a report on Saturday, June 13th. Citizens Jmp lowered KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Finally, Stifel Nicolaus upped their target price on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, March 26th.

Insider Transactions at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,239 shares of the company’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $26.78, for a total value of $59,960.42. Following the sale, the insider owned 150,260 shares of the company’s stock, valued at approximately $4,023,962.80. This represents a 1.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Nicole Sweeny sold 1,489 shares of the stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $26.78, for a total value of $39,875.42. Following the sale, the insider directly owned 59,291 shares in the company, valued at approximately $1,587,812.98. The trade was a 2.45% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 254,602 shares of company stock worth $4,656,670 over the last ninety days. 4.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of KalVista Pharmaceuticals by 3.7% during the third quarter. Vanguard Group Inc. now owns 2,501,119 shares of the specialty pharmaceutical company’s stock valued at $30,464,000 after buying an additional 88,720 shares during the period. Tudor Investment Corp ET AL acquired a new stake in KalVista Pharmaceuticals in the 3rd quarter worth about $24,360,000. State Street Corp boosted its stake in KalVista Pharmaceuticals by 21.3% in the 4th quarter. State Street Corp now owns 1,911,691 shares of the specialty pharmaceutical company’s stock worth $30,874,000 after buying an additional 336,195 shares during the last quarter. Vestal Point Capital LP boosted its stake in KalVista Pharmaceuticals by 152.0% in the 4th quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock worth $30,524,000 after buying an additional 1,140,000 shares during the last quarter. Finally, Parkman Healthcare Partners LLC boosted its stake in KalVista Pharmaceuticals by 155.5% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock worth $21,132,000 after buying an additional 1,055,940 shares during the last quarter.

KalVista Pharmaceuticals Stock Performance

Shares of KALV stock opened at $27.00 on Monday. The business’s fifty day moving average price is $24.87 and its 200 day moving average price is $19.25. KalVista Pharmaceuticals has a 1-year low of $9.83 and a 1-year high of $27.00. The firm has a market capitalization of $1.44 billion, a PE ratio of -7.80 and a beta of -0.12. The company has a debt-to-equity ratio of 8.18, a current ratio of 5.17 and a quick ratio of 5.10.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings data on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The company had revenue of $40.86 million during the quarter, compared to analysts’ expectations of $39.03 million. As a group, sell-side analysts forecast that KalVista Pharmaceuticals will post -1.19 EPS for the current fiscal year.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.